Celldex’s CSU drug could chal­lenge a No­var­tis can­di­date af­ter PhII

Celldex Ther­a­peu­tics’ an­ti-KIT an­ti­body hit the pri­ma­ry end­point in a mid-stage test in chron­ic spon­ta­neous ur­ticaria, with some an­a­lysts de­scrib­ing the da­ta as bet­ter than a No­var­tis ther­a­py that’s fur­ther ahead in de­vel­op­ment.

Celldex’s Phase II tri­al set three dos­es of bar­zolvolimab against place­bo in 208 pa­tients with chron­ic spon­ta­neous ur­ticaria (CSU) who were symp­to­matic de­spite an­ti­his­t­a­mine treat­ment, in­clud­ing some who were re­frac­to­ry to bi­o­log­ics such as No­var­tis and Genen­tech’s Xo­lair. There are cur­rent­ly no ap­proved treat­ments for pa­tients whose dis­ease is not con­trolled by Xo­lair.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER